Acasti Pharma To Showcase CaPre Clinical Data

Pharmaceutical Investing

Acasti Pharma will present new data for CaPre at the upcoming National Lipid Association Scientific Sessions.

Acasti Pharma (NASDAQ:ACST)(TSXV:ACST) will present new data for CaPre at the upcoming National Lipid Association Scientific Sessions.
As quoted in the press release:

Jean-François Lapointe, Ph.D, director of clinical development at Acasti, will present “Phase 1, Single-Dose, Comparative Bioavailability Study of CaPre, a Novel Omega-3 Derived from Krill Oil and Lovaza® under Fasting and Fed Conditions,” on May 20, 2017 from 12:10-12:30 p.m. ET in the Franklin B room at the Philadelphia Marriot Downtown.
“The data highlights the preserved exposure and perhaps retained efficacy in patients taking CaPre in either the fasted state or with a low-fat diet, which is the physician recommended diet for patients with severe hypertriglyceridemia,” said Jean-François Lapointe, Ph.D., Acasti’s director of clinical development. “The results of the bioavailability study support advancing CaPre into Phase 3 clinical development in order to build the evidence that CaPre may provide patients with severe hypertriglyceridemia a therapeutic treatment alternative that has a more comprehensive and positive impact on the major lipids associated with cardiovascular disease.”

Click here to read the full press release.


The Conversation (0)